Application of the MIC breakpoints based on pharmacokinetics and pharmacodynamics parameter in the clinical laboratory

Japanese Journal of Antibiotics

Volumn 56, Issue 6, 2003, Pages 697-704

  Komatsua, Masaru ^a,b   Nakamura, Akihiro ^a   Aihara, Masanori ^a,c   Shimakawa, Kouichi ^a   Iwasaki, Mizuho ^a   Nagasaka, Yoko ^a   Fukuda, Saori ^a   Matsuo, Syuji ^a  

^a TENRI HOSPITAL   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c Takane Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMPICILLIN; ANTIBIOTIC AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; BIAPENEM; CARBAPENEM; CEFACLOR; CEFAZOLIN; CEFDITOREN; CEFEPIME; CEFIXIME; CEFMETAZOLE; CEFOPERAZONE; CEFOTAXIME; CEFOTIAM; CEFPIROME; CEFPODOXIME; CEFTAZIDIME; CEFTIZOXIME; CEFTRIAXONE; FROPENEM; IMIPENEM; LATAMOXEF; MEROPENEM; PANIPENEM; PENICILLIN G; PIPERACILLIN;

ARTICLE; BACTERIAL PNEUMONIA; CALCULATION; DOSE CALCULATION; ENTEROBACTERIACEAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; PUBLICATION; STAPHYLOCOCCUS;

ANTI-BACTERIAL AGENTS; CLINICAL LABORATORY INFORMATION SYSTEMS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, BACTERIAL; LACTAMS; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; PRACTICE GUIDELINES; STREPTOCOCCUS PNEUMONIAE; TIME FACTORS;

EID: 0942287791     PISSN: 03682781     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. National Committee for Clinical Laboratory Standards: Performance standards for antimicrobial susceptibility testing; 12th informational supplement. NCCLS document M100-S12, 2002, National Committee for Clinical Laboratory Standards, Wayne, Pa, USA
2. CRAIG, W. A.: Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosin of mice and men. Clin. Infect. Dis., 26: 1-12, 1998
3. MACGOWAN, A. P. & R. WISE: Establishing MIC breakpoints and the interpretation of in vitro susceptibility tests. J. Antimicrob. Chemother. 48 (Suppl. S1): 17-28, 2001
4. GILBERT, D. N.; R. C. MOELLERING & M. A. SANDE: The Sanford Guide to Antimicrobial Therapy Thirty-third edition, 2003, Antimicrobiology Therapy, Inc. Hyde Park, Vt, USA
5. KUNIN, C. M.: Protein binding of antibiotics does affect their antistaphyloccal activity. J. Antimicrob. Chemother. 17: 263, 1986
6. CRAIG, W. A. & B. SUH: Theory and practical impact of binding of antimicrobials to serum proteins and tissue. Scand. J. Infect. Dis. 14 (Suppl.): 92-99, 1978
7. GEORGE, R. H.: The influence of protein binding on the antistaphylococcal activity of antibiotics. J. Antimicrob. Chemother. 17: 539-540, 1986
8. KUNIN, C. M.; W. A. CRAIG, M. KORNGUTH & R. MONSON: Influence of binding on the pharmacologic activity of antibiotics. Ann. N Y Acad. Sci. 26: 214-224, 1973
9. KUTI, J. L.; C. H. NIGHTINGALE & R. QUINTILIANI: Pharmacodynamic profiling of continuously infused piperacillin/tazobactam against Pseudomonas aeruginosa using Monte Carlo analysis. Diagn. Microbiol. Infect. Dis. 44: 51-57, 2002
10. AMBROSE, P. G. & D. M. GRASELA: The use of Monte Carlo simulation to examine pharmacodynamic variance of drugs: fluoroquinolone pharmacodynamics against Streptococcus pneumoniae. Diagn. Microbiol. Infect. Dis. 38: 151-157, 2000